PRESS RELEASE published on 01/09/2025 at 15:30, 1 year ago Formycon included in TecDAX Index of Deutsche Börse Formycon AG to be included in TecDAX Index of Deutsche Börse, enhancing visibility and market position. Company specializes in biosimilars for various disease areas Formycon AG Biosimilars Deutsche Börse TecDAX Index Technology Stocks
BRIEF published on 01/08/2025 at 14:35, 1 year ago Health Canada Approves Formycon's Biosimilar FYB202/Otulfi® Healthcare Costs Biosimilar Formycon Ustekinumab Canada Approval
BRIEF published on 01/08/2025 at 14:35, 1 year ago Santé Canada approuve le médicament biosimilaire FYB202/Otulfi® de Formycon Formycon Ustekinumab Coûts Des Soins De Santé Biosimilaire Approbation Du Canada
PRESS RELEASE published on 01/08/2025 at 14:30, 1 year ago Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Formycon and Fresenius Kabi Canada obtain Health Canada's approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Health Canada Approval Biosimilar Formycon Stelara Fresenius Kabi Canada
BRIEF published on 12/11/2024 at 16:31, 1 year 1 month ago Formycon AG Maintains Strong Growth Prospects Amidst Challenging Market Conditions FDA Approval Revenue Decline Formycon AG Biosimilars Stelara Launch
BRIEF published on 12/11/2024 at 16:31, 1 year 1 month ago Formycon AG maintient de solides perspectives de croissance dans un contexte de marché difficile Formycon AG Baisse Des Revenus Approbation De La FDA Biosimilaires Lancement De Stelara
PRESS RELEASE published on 12/11/2024 at 16:26, 1 year 1 month ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research publishes update on Formycon AG with BUY rating and EUR 82.00 price target, highlighting decline in revenue and upcoming biosimilar launches First Berlin Equity Research BUY Rating Formycon AG EUR 82.00 Price Target Biosimilar Launches
BRIEF published on 12/09/2024 at 06:35, 1 year 1 month ago MS Pharma to Commercialize FYB202 in MENA MENA Region Formycon AG Biosimilars MS Pharma FYB202
BRIEF published on 12/09/2024 at 06:35, 1 year 1 month ago MS Pharma va commercialiser FYB202 dans la région MENA Formycon AG MS Pharma Région MENA FYB202 Biosimilaires
PRESS RELEASE published on 12/09/2024 at 06:30, 1 year 1 month ago MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region Formycon AG and MS Pharma sign licensing and supply agreement for the commercialization of FYB202/ustekinumab biosimilar in MENA region, expanding patient access to vital treatments MENA Region Formycon AG MS Pharma FYB202 Ustekinumab
Published on 02/04/2026 at 15:00, 4 minutes ago Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale
Published on 02/04/2026 at 14:30, 34 minutes ago Core Silver Significantly Expands Copper-Molybdenum Footprint at Laverdiere Through Soil Sampling
Published on 02/04/2026 at 14:30, 34 minutes ago Klondike Gold Drills 600 Meter Step Out from Lone Star Deposit and Intersects Broad Interval of Gold Mineralization Extending Lone Star Target Zone to the Southwest
Published on 02/04/2026 at 14:00, 1 hour 4 minutes ago GameSquare Appoints Amaree Tanawong as Chief Operating Officer
Published on 02/04/2026 at 14:49, 14 minutes ago Edison issues report on Invesco Asia Dragon Trust (LSE: IAD)
Published on 02/04/2026 at 14:45, 19 minutes ago Floyd Mayweather Faces Greek Icon 'Iron' Mike Zambidis in Athens at BATTLE of the LEGENDS
Published on 02/04/2026 at 14:30, 34 minutes ago ADS-TEC Energy strengthens market position in battery storage sector in Austria
Published on 02/04/2026 at 14:14, 50 minutes ago Verve Group SE Successfully Places Subsequent Senior Unsecured Bonds of EUR 50 million
Published on 02/04/2026 at 14:05, 59 minutes ago Zeta Network Group Outlines Strategic Focus on Real-World Asset Tokenisation as Part of Institutional Digital Treasury Strategy
Published on 02/04/2026 at 12:50, 2 hours 14 minutes ago Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Published on 02/04/2026 at 11:59, 3 hours 5 minutes ago LNA Santé : Répartition de capital et des droits de vote attachés aux actions au 31/01/2026
Published on 02/04/2026 at 11:51, 3 hours 12 minutes ago Janvier 2026 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Published on 02/03/2026 at 18:00, 21 hours 4 minutes ago Mint dépasse ses ambitions annoncées pour 2025 grâce à des succès commerciaux majeurs dans le BtoB
